BSX Appeal Denied by U.S. Supreme Court

It appears that Natick, MA-based Boston Scientific (NYSE: BSX) will be forced to pay medical products giant Johnson & Johnson the full $703 million patent-infringement award finalized last week by the U.S. District Court of Delaware, after the U.S. Supreme Court declined yesterday to hear the company’s appeal of the case. Johnson & Johnson claimed that Boston Scientific infringed on a coronary artery stent patent owned by its Cordis division. A $521 million judgment against Minneapolis-based Medtronic will also stand, as Medtronic did not appeal the Delaware court’s judgment.

Wade Roush is a freelance science and technology journalist and the producer and host of the podcast Soonish. Follow @soonishpodcast

Trending on Xconomy